Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L acquired 27,502 shares of the business's stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $10.98 per share, with a total value of $301,971.96. Following the completion of the acquisition, the director now directly owns 7,981,725 shares in the company, valued at approximately $87,639,340.50. This represents a 0.35 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Suvretta Capital Management, L also recently made the following trade(s):
- On Tuesday, December 3rd, Suvretta Capital Management, L acquired 42,000 shares of Benitec Biopharma stock. The shares were purchased at an average cost of $9.60 per share, for a total transaction of $403,200.00.
Benitec Biopharma Trading Up 3.6 %
Shares of NASDAQ:BNTC opened at $12.00 on Friday. The company has a 50-day moving average price of $10.89 and a 200-day moving average price of $9.54. The company has a market cap of $278.59 million, a price-to-earnings ratio of -4.23 and a beta of 0.89. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $13.29.
Institutional Inflows and Outflows
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
A number of hedge funds and other institutional investors have recently bought and sold shares of BNTC. Nantahala Capital Management LLC purchased a new stake in Benitec Biopharma in the second quarter worth $5,881,000. Simplify Asset Management Inc. raised its holdings in Benitec Biopharma by 127.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 116,535 shares of the biotechnology company's stock worth $1,071,000 after purchasing an additional 65,319 shares in the last quarter. Suvretta Capital Management LLC lifted its position in shares of Benitec Biopharma by 422.0% in the 3rd quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company's stock worth $81,139,000 after purchasing an additional 7,137,763 shares during the period. GAMMA Investing LLC boosted its stake in shares of Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 1,102 shares in the last quarter. Finally, Acuta Capital Partners LLC purchased a new position in shares of Benitec Biopharma during the third quarter valued at about $274,000. Institutional investors own 52.19% of the company's stock.
Analyst Ratings Changes
A number of research analysts have commented on the stock. Piper Sandler reiterated an "overweight" rating on shares of Benitec Biopharma in a research report on Friday, October 18th. Guggenheim reiterated a "buy" rating and issued a $17.00 target price on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. HC Wainwright began coverage on shares of Benitec Biopharma in a research note on Monday, December 16th. They issued a "buy" rating and a $28.00 price target for the company. JMP Securities raised their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the company a "market outperform" rating in a research note on Monday, October 14th. Finally, Robert W. Baird initiated coverage on Benitec Biopharma in a research note on Friday, December 13th. They issued an "outperform" rating and a $30.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $24.43.
Check Out Our Latest Research Report on BNTC
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
